Histologically confirmed diagnosis of adenocarcinoma of the rectumXx_NEWLINE_xXThe patient must have histologically confirmed, gastric carcinoma, including gastroesophageal junction (GEJ) adenocarcinoma (patients with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ)Xx_NEWLINE_xXDiagnosis of rectal adenocarcinomaXx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)Xx_NEWLINE_xXPatients must have endometrial carcinoma including endometrioid adenocarcinoma, adenocarcinoma with squamous differentiation, mucinous adenocarcinoma, squamous cell carcinoma, mixed carcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, and serous adenocarcinoma histologiesXx_NEWLINE_xXPathologically (histologically) proven diagnosis of prostate adenocarcinoma; prostatectomy must have been performed within 10 years prior to Step 1 registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assistedXx_NEWLINE_xXPatients must have a histologic diagnosis of pancreatic adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectumXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of the rectumXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed GI malignancy for which mFOLFOX6 is considered an appropriate treatment (e.g., gastric cancer [GC], colorectal carcinoma, pancreatic adenocarcinoma)Xx_NEWLINE_xXCytologically- or histologically-confirmed pancreatic adenocarcinoma or poorly differentiated pancreatic carcinoma that is metastatic to distant sites\r\n* Other histologies such as neuroendocrine and acinar cell carcinoma are excludedXx_NEWLINE_xXProcurement: Any patient with biopsy proven pancreatic adenocarcinomaXx_NEWLINE_xXPancreatic ductal adenocarcinoma (PDAC)Xx_NEWLINE_xXProstate adenocarcinoma (PAC)Xx_NEWLINE_xXDocumented primary diagnosis of histologic- or cytologic-confirmed adenocarcinoma of the stomach or gastroesophageal junction.Xx_NEWLINE_xXThere must be histologic confirmation of a diagnosis of colorectal adenocarcinoma.Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Histologically confirmed metastatic adenocarcinoma of the pancreasXx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Histologically confirmed metastatic adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the EGJXx_NEWLINE_xXHistologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.Xx_NEWLINE_xXThe diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% uterine papillary serous (UPSC) adenocarcinoma in the specimenXx_NEWLINE_xXNon-small cell lung adenocarcinoma or squamous cell carcimonaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate. No evidence of neuroendocrine differentiation or small cell features.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the breastXx_NEWLINE_xXHistologically confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permittedXx_NEWLINE_xXSubject must have histologically-confirmed diagnosis of prostate adenocarcinoma and have received primary surgical management by radical prostatectomyXx_NEWLINE_xXHistologically confirmed prostate adenocarcinoma within 365 days prior to randomization.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and/or radiotherapy.Xx_NEWLINE_xXGastric or gastroesophageal junction adenocarcinomaXx_NEWLINE_xXPatients with exocrine pancreatic adenocarcinoma must have predominant adenocarcinoma histology. Patients must have received prior therapy with a gemcitabine-based or 5FU-based regimen, if eligible, and should have received no more than 1 systemic regimen in the unresectable or metastatic setting.Xx_NEWLINE_xXHistologically confirmed breast adenocarcinoma that is unresectable loco-regionally advanced or metastatic.Xx_NEWLINE_xXHistology other than adenocarcinomaXx_NEWLINE_xXAny solid malignancy known to be MSI high/MMR deficient per local test results, including but not limited to: CRC, stomach adenocarcinoma, esophageal adenocarcinoma and endometrial cancerXx_NEWLINE_xXPathologically documented diagnosis of colorectal adenocarcinoma.Xx_NEWLINE_xXpure small cell, neuroendocrine or other variant (non-adenocarcinoma) prostate cancer histologyXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed prostate adenocarcinomaXx_NEWLINE_xXHistologic or cytologic diagnosis of adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistological or cytological diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXHistologically proven (squamous cell or adenocarcinoma) esophageal or gastro- esophageal junction cancer (core biopsy required)Xx_NEWLINE_xXHistologically confirmed prostate adenocarcinomaXx_NEWLINE_xXHistologically-confirmed adenocarcinoma of the prostateXx_NEWLINE_xXMales diagnosed with histologically confirmed, adenocarcinoma of the prostate based on core biopsy prior to study entry from transrectal ultrasonography (TRUS)Xx_NEWLINE_xXHistologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell featuresXx_NEWLINE_xXHave a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostateXx_NEWLINE_xXConfirmation of adenocarcinoma of the prostate that is documented by one of the following: pathology report or clinic note with documented history of prostate cancerXx_NEWLINE_xXHistologically confirmed unresectable metastatic colorectal adenocarcinomaXx_NEWLINE_xXHistological confirmation of adenocarcinoma of the prostate within 6 months of study enrollmentXx_NEWLINE_xXPart D: Have metastatic pancreatic ductal adenocarcinoma (dose escalation and dose expansion)Xx_NEWLINE_xXThe patient has a histologically or cytologically confirmed metastatic pancreatic adenocarcinoma.Xx_NEWLINE_xXPancreatic adenocarcinoma.Xx_NEWLINE_xXPatients must have a histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic, unresectable, or recurrentXx_NEWLINE_xXHistologically confirmed colorectal adenocarcinomaXx_NEWLINE_xXHistologically documented adenocarcinoma prostate cancer confirmed by a pathology report from prostate biopsy or a radical prostatectomy specimen; if prostatic tumor is of mixed histology, > 50% of the tumor must be adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients with cytologic evidence of adenocarcinoma in situXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinomaXx_NEWLINE_xXPatient has definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. Patients with islet cell or neuroendocrine neoplasms are excluded.Xx_NEWLINE_xXSubjects must have a histologically confirmed pancreatic adenocarcinoma that has had an R0 (negative margins) or R1 (microscopically positive margins) resectionXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic or unresectable adenocarcinoma of the colon or rectumXx_NEWLINE_xXPatients must have histologically or cytologically documented advanced or metastatic adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically confirmed prostate adenocarcinoma (within 365 days of randomization) at intermediate risk for reoccurrence determined by at least one of the following: Gleason Score 7, PSA > = 10 and < = 20, T stage T2b - T2cXx_NEWLINE_xXHistologically confirmed prostate adenocarcinoma at the time of surgeryXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate and the availability archival prostate tumor sample is requiredXx_NEWLINE_xXParticipants with histologically or cytologically confirmed diagnosis of adenocarcinoma of the GEJ or stomach will be enrolled in this studyXx_NEWLINE_xXHistologically or cytologically documented adenocarcinoma or squamous cell carcinoma of the cervical or thoracic esophagus or gastroesophageal junction or cardia of stomachXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically proven pancreatic adenocarcinoma (subjects with endocrine or acinar pancreatic carcinoma are not eligible)Xx_NEWLINE_xXHistologically confirmed metastatic adenocarcinoma of the prostate without histological neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate, who meet the following criteria:Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the colon or the rectum that is metastatic or unresectable.Xx_NEWLINE_xXHave histologically or cytologically confirmed metastatic or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically and cytologically documented diagnosis as gastroesophageal adenocarcinoma.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXSubjects must have a biopsy confirmed diagnosis of squamous cell, adenocarcinoma, or adenosquamous carcinoma of the cervix. Histologic confirmation of the original primary tumor is required.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of prostate.Xx_NEWLINE_xXHistologic diagnosis of prostate adenocarcinoma\r\n* Pure small cell carcinoma will be excluded; however, component of neuroendocrine /small cell differentiation will be allowed provided that adenocarcinoma constitutes majority of the tissue specimenXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate without signet cell or small cell featuresXx_NEWLINE_xXCytologic or biopsy confirmed adenocarcinoma of the pancreatic head, body or tailXx_NEWLINE_xXHistologic confirmation of adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed diagnosis of colorectal adenocarcinomaXx_NEWLINE_xXCytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction.Xx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXPatients with the following histologic epithelial cell types are eligible:\r\n* Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specifiedXx_NEWLINE_xXHistologically-confirmed diagnosis of prostate adenocarcinoma; variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate, are not permittedXx_NEWLINE_xXHistologic confirmation of prostate adenocarcinoma diagnosisXx_NEWLINE_xXPatients must have recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, diagnosed within 6 months of completing their most recent platinum-containing chemotherapy; histologic documentation of the original primary tumor is required via a pathology report; \r\n* Patients with the following histologic cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.)Xx_NEWLINE_xXPatients must have a diagnosis endometrial carcinoma on a tissue sample obtained at MSK (biopsy); patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed adenocarcinoma of the prostate with no histological variants (such as small cell, sarcomatoid, pure ductal cancer, transitional cell carcinoma).Xx_NEWLINE_xXHave histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate (with previous diagnostic tissue available for tumor marker analysis)Xx_NEWLINE_xXGleason 7 – 10, cT2a – cT3b adenocarcinoma of the prostate with plans for radical prostatectomyXx_NEWLINE_xXHistologically confirmed pancreatic adenocarcinoma with initial diagnosis within 6 weeks of consentXx_NEWLINE_xXHas histologically or cytologically documented adenocarcinoma NSCLC.Xx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate.Xx_NEWLINE_xXPathologically confirmed adenocarcinoma of the esophagus, GEJ or stomach.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without signet cell, or small cell features.Xx_NEWLINE_xXHistologically proven invasive adenocarcinoma of breastXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; mixed histology will be included as long as the predominant histology is adenocarcinomaXx_NEWLINE_xXEvidence of neuroendocrine tumor, duodenal adenocarcinoma, or ampullary adenocarcinomaXx_NEWLINE_xXPatients must have measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma; largest tumor diameter =< 5 cm\r\n* NOTE: histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (NOS)\r\n* NOTE: measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1)Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic pancreatic adenocarcinoma that has progressed on one or more chemotherapy regimens.Xx_NEWLINE_xXFor individual baskets: Appendiceal adenocarcinoma: Must not have clinically symptomatic malignant bowel obstruction; Cutaneous squamous cell carcinoma: none; Small bowel adenocarcinoma: must not have clinically symptomatic malignant small bowel obstructionXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of colorectal or pancreatic originXx_NEWLINE_xXPatients must have histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert I-III) adenocarcinoma confirmed by the Laboratory of Pathology, National Cancer Institute (NCI)Xx_NEWLINE_xXHas histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;Xx_NEWLINE_xXHistologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as documented via CT scan (within 6 weeks of Screening);Xx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the pancreasXx_NEWLINE_xXHas a pathologic diagnosis of invasive esophageal, gastroesophageal or gastric adenocarcinomaXx_NEWLINE_xXHistological proof of adenocarcinoma of the prostateXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXProgressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistological or cytological proof of prostate adenocarcinoma (Note: small-cell carcinoma of the prostate is not permitted)Xx_NEWLINE_xXThe presence of metastatic pancreatic adenocarcinomaXx_NEWLINE_xXDiagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or cystadenocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic diseaseXx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXHistologically-confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed mPAC (mixed histology is acceptable as long as the predominant histology is pancreatic adenocarcinoma)Xx_NEWLINE_xXPatients must have metastatic histologically or cytologically confirmed pancreatic adenocarcinoma or sarcoma (soft tissue or bone) for which progression was documented for at least one line of therapyXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostate and: Gleason > 8 OR prostatic specific antigen (PSA) > 20 and more than 1 positive coreXx_NEWLINE_xXPancreatic ductal adenocarcinoma: 1) pancreatic ductal adenocarcinoma patient with KRAS point mutation at codon G12 or G13; in addition to the above inclusion criteria, first 5 patients from both non-small cell lung cancer and pancreatic ductal adenocarcinoma patients will need to agree to mandatory pre- and post-treatment tumor biopsiesXx_NEWLINE_xXHistologically (archival tissue) confirmed adenocarcinoma of the rectum that begins within 12 cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy with no evidence of distant metastasisXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate (clinical stage T1c–T3b, N0, M0) without involvement of lymph nodes, bone, or visceral organsXx_NEWLINE_xXHave histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma based on pathology reportXx_NEWLINE_xXHistologically proven persistent or recurrent adenocarcinoma of the prostate following prior external beam radiation therapyXx_NEWLINE_xXHistologically or cytopathologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed prostate adenocarcinomaXx_NEWLINE_xXHistologically confirmed primary non-metastatic adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed recurrent, advanced or metastatic pancreatic ductal adenocarcinoma as determined by National Cancer Institute (NCI) Laboratory of PathologyXx_NEWLINE_xXHistologic or cytologic diagnosis of adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the pancreas or ampulla of Vater; at least the majority of the histopathologic specimen must be identified as adenocarcinoma as opposed to another histologic subtype; in patients with a diagnosis of recurrent disease (based on radiographic progression and/or rising CA19-9 levels) and a history of a biopsy-proven adenocarcinoma of the pancreas or the ampulla of Vater, repeat biopsy of the recurrence site is not required for participation of the trialXx_NEWLINE_xXMust have histologic or cytologic confirmation of recurrent metastatic pancreatic adenocarcinoma based on standard diagnostic criteria. Recurrence must be documented by diagnostic biopsy.Xx_NEWLINE_xXMetastatic or relapsed Gastric cancer (adenocarcinoma) (module 4)Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma involving the gastroesophageal junction or gastric cardiaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate as documented by a minimum 12 core prostate biopsy completed within 1-year of enrollment (note: most recent prostate biopsy must have demonstrated prostatic adenocarcinoma)Xx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXDiagnosis of ductal adenocarcinoma of the pancreas (PDAC).Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients with histologically or cytologically confirmed metastatic adenocarcinoma of the pancreasXx_NEWLINE_xXPatients with histologically proven, surgically unresectable, locally advanced pancreatic adenocarcinoma (at diagnosis) or with mixed cell type with predominant histology of adenocarcinoma (by NCCN guidelines)Xx_NEWLINE_xXHistologically or cytologically confirmed newly diagnosed treatment-naive metastatic adenocarcinoma of the pancreas with metastatic disease diagnosed no more than 8 weeks prior to enrollmentXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically-proven prostate adenocarcinoma\r\n* Gleason score 6-10 based on a review of the prostate core biopsies at Moffitt Cancer CenterXx_NEWLINE_xXDoes not have a diagnosis of prostate adenocarcinomaXx_NEWLINE_xXBiopsy positive for adenocarcinoma of the prostate containing any quantity of Gleason 3 component (e.g. Gleason score 3+3, 3+4, 4+3)Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction (EAC)Xx_NEWLINE_xXHistologically or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for metastatic disease and without evidence of disease progression on treatmentXx_NEWLINE_xXHistology other than adenocarcinoma (neuroendocrine or acinar cell)Xx_NEWLINE_xXNew diagnosis of histologically confirmed adenocarcinoma of the rectumXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed breast adenocarcinoma, colorectal adenocarcinoma, gastroesophageal cancer (adenocarcinoma or squamous cell carcinoma), melanoma, non-small cell lung cancer, or clear cell renal cell carcinoma with liver metastases or hepatocellular carcinoma with known disease progression.Xx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)Xx_NEWLINE_xXHistologically confirmed diagnosis of adenocarcinoma of the prostate and most recent biopsy within 365 days of study enrollmentXx_NEWLINE_xXHistologically-proven invasive adenocarcinoma of the pancreasXx_NEWLINE_xXHave a newly diagnosed, biopsy-proven adenocarcinoma of the head, neck and uncinate of the pancreas, and is a candidate for a pancreaticoduodenectomy; if the biopsy is not sufficient for diagnosis, the patient can be considered to meet eligibility if the study team agrees that clinically the patient’s tumor is suspected to be adenocarcinomaXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate (the availability archival prostate tumor sample is preferred not required)Xx_NEWLINE_xXHistologic confirmation of diagnosis of adenocarcinoma of the prostate will be required by biopsyXx_NEWLINE_xXAdenocarcinoma of the pancreasXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXDocumented pathologic confirmation of prostate adenocarcinomaXx_NEWLINE_xXPatients with EGFR T790M NSCLC (adenocarcinoma)Xx_NEWLINE_xXBiopsy-proven diagnosis of rectal adenocarcinomaXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the pancreas (within the last 90 days)Xx_NEWLINE_xXHistologically confirmed primary non-metastatic adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed metastatic colorectal adenocarcinoma (colon, rectal, colorectal, appendiceal cancer) or small bowel that is not resectableXx_NEWLINE_xXHistologically confirmed metastatic gastric or esophagogastric junction (type I, II, III Siewert) adenocarcinomaXx_NEWLINE_xXPathologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate from a prostate biopsy or prostatectomy specimen (primary site), or histological confirmation of adenocarcinoma/carcinoma in a metastatic site of disease in the setting of elevated prostate specific antigen (PSA) and imaging consistent with metastatic prostate cancer, or history of prostate cancer with documented metastasis, or histologically confirmed other solid tumor malignancy, multiple myeloma, or plasmacytoma with pathological confirmation of metastasisXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXHistologically and/or cytologically confirmed adenocarcinoma of the pancreas, clinical stage T1-4, N0-1, M0Xx_NEWLINE_xXHistologically-confirmed adenocarcinoma of the prostateXx_NEWLINE_xXThe following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner’s tumor, or adenocarcinoma not otherwise specified (NOS)Xx_NEWLINE_xXStatus post radical prostatectomy for histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostate obtained within 6 months of screening; patients in whom a diagnosis of high-risk localized or locally-advanced prostatic adenocarcinoma is suspected based on a serum PSA > 20 ng/mL or clinical T3 disease by digital rectal examination, but who have not yet undergone diagnostic prostate biopsy, will be eligible for screening and initial MRI and targeted prostate cancer biopsies which will be obtained at the same time as diagnostic biopsies; those patients in whom the diagnostic biopsies confirm prostatic adenocarcinoma will be permitted to continue with study treatment if they meet all additional eligibility criteriaXx_NEWLINE_xXPathologic or cytologic documentation of pancreatic adenocarcinomaXx_NEWLINE_xXPatients must have pathologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXBiopsy proven pancreatic adenocarcinomaXx_NEWLINE_xXHave histologically proven adenocarcinoma of the colon or rectumXx_NEWLINE_xXPancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided)Xx_NEWLINE_xXHistologically confirmed diagnosis of adenocarcinoma of the prostate within one year of study entry; evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD AndersonXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the rectum in patients with no prior therapy who are candidate for surgical resectionXx_NEWLINE_xXAll patients must have histologically confirmed prostate adenocarcinoma, with biopsies obtained within twelve months of patient registrationXx_NEWLINE_xXHistologically proven adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically documented adenocarcinoma or squamous cell carcinoma of the cervical or thoracic esophagus or gastroesophageal junction or cardia of stomachXx_NEWLINE_xXHistologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer comprising of > 50% of the tumor including neuroendocrine features and small cell carcinoma of the prostate are excludedXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostate diagnosed (with ?10 core biopsy) within 6 months of screening. The biopsy that was used for this diagnosis must be submitted for central pathology review.Xx_NEWLINE_xXHistologic or cytological diagnosis of recurrent or metastatic pancreas adenocarcinoma (PCA) who present for first line chemotherapy treatmentXx_NEWLINE_xXHistological or cytological documentation of adenocarcinoma of the colon or rectumXx_NEWLINE_xXPatients with adenocarcinoma of the prostate that in the opinion of the urologist could be resected after response to systemic therapy; ductal adenocarcinoma is permittedXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the pancreas that has been resected with a close (< 2.5mm) or positive margin based on surgical and pathological findingsXx_NEWLINE_xXPathologically (histologically) proven diagnosis of prostatic adenocarcinomaXx_NEWLINE_xXPatients must have a histologically documented peritoneal carcinomatosis from either colorectal or appendiceal adenocarcinomaXx_NEWLINE_xXHistologically confirmed prostate adenocarcinoma within 365 days of registrationXx_NEWLINE_xXPatients with cytologic evidence of adenocarcinoma in situXx_NEWLINE_xXHistologically proven prostate adenocarcinoma:\r\n* Gleason score 2-7 \r\n* Biopsy within one year of date of registrationXx_NEWLINE_xXNo histologic documentation of breast adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXSubject has histologically confirmed diagnosis of Gastric or GEJ adenocarcinoma.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPathological finding consistent with small cell, neuroendocrine carcinoma of the prostate or any other histology different than adenocarcinomaXx_NEWLINE_xXDiagnosis of prostate adenocarcinoma as confirmed by the investigatorXx_NEWLINE_xXGroup 5: Pancreatic Ductal Adenocarcinoma (Part B)Xx_NEWLINE_xXHistologically confirmed invasive well-moderately differentiated rectal adenocarcinoma diagnosed within 90 days prior to enrollment.Xx_NEWLINE_xXHistologically confirmed prostate cancer (not exclusive of adenocarcinoma)Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed colorectal adenocarcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the breastXx_NEWLINE_xXMales with histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate without morphologic neuroendocrine differentiation or small cell features.Xx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate (excluding predominant small cell histology)Xx_NEWLINE_xXHistologically or cytologically confirmed colorectal adenocarcinomaXx_NEWLINE_xXHistory of histologically confirmed, clinical localized adenocarcinoma of the prostate treated with radical prostatectomy with definitive intentXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed locally advanced or borderline resectable pancreatic ductal adenocarcinoma. Patients with clinical suspicion of pancreatic adenocarcinoma can be enrolled for pre-treatment biopsy, and must be histologically confirmed to have adenocarcinoma before being treated on study. Patients with squamous carcinoma, adenosquamous carcinoma or neuroendocrine tumor will be excludedXx_NEWLINE_xXHistologically confirmed unresectable metastatic colorectal adenocarcinomaXx_NEWLINE_xXCytologically confirmed pancreatic adenocarcinomaXx_NEWLINE_xXMetastatic colorectal, pancreatic, gastroesophageal or biliary tract adenocarcinoma not amenable to curative resectionXx_NEWLINE_xXHistologically-confirmed advanced or metastatic unresectable gastric carcinoma, or adenocarcinoma of the gastroesophageal junctionXx_NEWLINE_xXHistologically or cytologically confirmed colorectal adenocarcinoma, with metastatic disease documented on diagnostic imaging studiesXx_NEWLINE_xXHistologically confirmed stage IV colorectal adenocarcinoma without any prior systemic treatmentXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXNon-adenocarcinoma histologyXx_NEWLINE_xXHistological or cytologic evidence of adenocarcinoma of the prostate confirmed at local institutionXx_NEWLINE_xXHistological confirmation of adenocarcinoma of the breastXx_NEWLINE_xXSubjects must have biopsy-confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients must have recurrent or persistent endometrial cancer (endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma or adenocarcinoma not otherwise specified [NOS]); histologic confirmation of the primary tumor is requiredXx_NEWLINE_xXPathologically confirmed diagnosis of prostate adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate (biopsy within one year of enrollment)Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHave histologically proven adenocarcinoma of the pancreas; patients with mixed histology will be excludedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients with EGFR/ALK/ROS-1+ lung adenocarcinomaXx_NEWLINE_xXDiagnosis of adenocarcinoma of the prostate, confirmed by H. Lee (L.) Moffitt Cancer Center reviewXx_NEWLINE_xXHistology other than adenocarcinomaXx_NEWLINE_xXPHASE II: Patients must have histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas with no prior systemic therapy for metastatic diseaseXx_NEWLINE_xXHistologically documented diagnosis of pancreatic adenocarcinomaXx_NEWLINE_xXPatients must have recurrent or persistent endometrial carcinoma, which is refractory to curative therapy or established treatments; histologic confirmation of the original primary tumor is required\r\n* Patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, mixed epithelial carcinoma, uterine clear cell carcinoma, and adenocarcinoma not otherwise specified (N.O.S.)Xx_NEWLINE_xXHistologically or cytologically proven diagnosis of adenocarcinoma of the pancreas prior to registrationXx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXPatients must have histologically or cytologically-confirmed pancreatic adenocarcinomaXx_NEWLINE_xXCytologically or histologically confirmed pancreatic adenocarcinoma (excluding islet cell or ampullary tumors) that is metastatic or unresectableXx_NEWLINE_xXPatients with histopathologically proven adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed metastatic adenocarcinoma of the lungXx_NEWLINE_xXHER2 expressing adenocarcinoma of the esophagus centrallyXx_NEWLINE_xXPatients with the following histologic cell types are eligible: \r\n* Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell carcinoma, malignant Brenner's tumor, adenocarcinoma not otherwise specified (N.O.S.) or carcinosarcomaXx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXHigh-grade serous adenocarcinomaXx_NEWLINE_xXEndometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or malignant Brenner's tumor.Xx_NEWLINE_xXThe diagnosis must be histologically confirmed by a gynecologic pathologist as containing >= 10% UPSC adenocarcinoma in the specimenXx_NEWLINE_xXAll patients must have a histologically or cytologically proven diagnosis of adenocarcinoma of the prostate; all patients must have metastatic disease as evidenced by soft tissue and/or bony metastases prior to initiation of androgen deprivation therapyXx_NEWLINE_xXPatients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified (N.O.S.)Xx_NEWLINE_xXHistologically confirmed, castrate-resistant adenocarcinoma of the prostateXx_NEWLINE_xXThe participant has a diagnosis of gastric or GEJ adenocarcinoma.Xx_NEWLINE_xXSubjects must have documented histological or cytological evidence of adenocarcinoma of the prostate.Xx_NEWLINE_xXHistologically or cytologically confirmed prostate adenocarcinomaXx_NEWLINE_xXHistologically documented adenocarcinoma (including the histologic variants of adenocarcinoma) of the colon or rectumXx_NEWLINE_xXHistologically confirmed unilateral primary invasive adenocarcinoma of the breastXx_NEWLINE_xXHas histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histologyXx_NEWLINE_xXHistologically confirmed breast adenocarcinoma that is unresectable loco regional, or metastaticXx_NEWLINE_xXMust have histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.Xx_NEWLINE_xXPatients must have pathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed diagnosis of gastric or GEJ adenocarcinomaXx_NEWLINE_xXFor gastric or GEJ adenocarcinoma:Xx_NEWLINE_xXFor gastric or GEJ adenocarcinoma, prior treatment with any taxaneXx_NEWLINE_xXHistological or cytological confirmation of metastatic or recurrent gastric or gastroesophageal junction adenocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features;Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic pancreatic ductal adenocarcinomaXx_NEWLINE_xXPatients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma\r\n* Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible:\r\n** Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)Xx_NEWLINE_xXBiopsy-confirmed adenocarcinoma of the prostate. Biopsy (minimum 10 cores) obtained ? 6 weeks and ? 6 months before treatment, or at the discretion of PI.Xx_NEWLINE_xXPatients must have histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligibleXx_NEWLINE_xXHas histologically confirmed non-resectable, metastatic gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the rectumXx_NEWLINE_xXadenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is undetectable;Xx_NEWLINE_xXHistologically confirmed, locally confined adenocarcinoma of the prostateXx_NEWLINE_xXHistologically-confirmed gastric or GEJ adenocarcinoma (Siewert type II/III classification) OrXx_NEWLINE_xXHistologically-confirmed inoperable superior, medial, or distal third esophageal adenocarcinoma (Siewert type I classification may be included, provided there is no mixed histology)Xx_NEWLINE_xXHistological or cytological diagnosis of ductal adenocarcinoma of the pancreas.Xx_NEWLINE_xXPatients must have histologically or cytologically documented pancreatic adenocarcinoma; patients with pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligibleXx_NEWLINE_xXSubject is diagnosed with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell or small cell histology.Xx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the colon or rectumXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, signet cell, or small cell features;Xx_NEWLINE_xXPatients must have newly diagnosed, untreated metastatic histologically or cytologically documented pancreatic adenocarcinoma; patients must not have known history of brain metastasesXx_NEWLINE_xXPart B: Pancreatic AdenocarcinomaXx_NEWLINE_xXPart B: Esophagogastric Adenocarcinoma:Xx_NEWLINE_xXHistologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinomaXx_NEWLINE_xXHistologically confirmed inoperable advanced adenocarcinoma of the colon or rectumXx_NEWLINE_xXHistologically confirmed inoperable advanced adenocarcinoma of the colon or rectumXx_NEWLINE_xXSpecific eligibility criteria for Part 2 CRPC expansion cohort: Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuously medically castrated (for >=8 weeks prior to pre-screening).Xx_NEWLINE_xXHistologically confirmed (either previously or newly biopsied) metastatic unresectable pancreatic adenocarcinoma, including with intraductal papillary mucinous neoplasm.Xx_NEWLINE_xXPrior history of invasive adenocarcinoma of colon or rectum.Xx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXDiagnosis of prostate adenocarcinoma as confirmed by the investigatorXx_NEWLINE_xXHas histopathologically confirmed gastric or GEJ adenocarcinoma with documented disease progression after 0-2 prior lines of systemic therapyXx_NEWLINE_xXHas histologically confirmed biliary tract adenocarcinoma with documented progression after 1-2 prior lines of systemic therapyXx_NEWLINE_xXPatients with adenocarcinoma of unknown primary are excludedXx_NEWLINE_xXMetastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not eligible.Xx_NEWLINE_xXHistologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)Xx_NEWLINE_xXThe subject has histologically or cytologically proven adenocarcinoma of the breast that is HER2+Xx_NEWLINE_xXSubjects must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma; subjects with islet cell neoplasms are excludedXx_NEWLINE_xXHistologically proven colorectal adenocarcinomaXx_NEWLINE_xXAppendiceal adenocarcinoma basket\r\n* Metastatic appendiceal adenocarcinoma\r\n* Not considered candidate for curative surgeryXx_NEWLINE_xXHistologically confirmed and documented disease to include: adenocarcinoma NOS (not otherwise specified), clear cell adenocarcinoma, endometrioid adenocarcinoma, malignant Brenner’s tumor, mixed epithelial carcinoma, mucinous adenocarcinoma, serous adenocarcinoma, transitional cell carcinoma, and undifferentiated carcinomaXx_NEWLINE_xXadenocarcinoma of the pancreas,Xx_NEWLINE_xXtriple-negative adenocarcinoma of the breastXx_NEWLINE_xXnon-small-cell adenocarcinoma of the lungXx_NEWLINE_xXHistological or cytological evidence of prostate adenocarcinoma.Xx_NEWLINE_xXHistologic confirmation of adenocarcinoma of the prostate by biopsy;Xx_NEWLINE_xXTumors of adenocarcinoma, melanoma, small cell and basal cell histology are excludedXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma.Xx_NEWLINE_xXPatients with a histologic diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXSmall cell or other (non-adenocarcinoma) variant prostate cancer histologyXx_NEWLINE_xXHistologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that FOLFIRABRAX is a reasonable therapeutic optionXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed untreated metastatic pancreatic adenocarcinoma; subjects with islet cell neoplasms are excluded; subjects with mixed histology will be excludedXx_NEWLINE_xXHave a histopathologically confirmed diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. All histologies of nonsquamous cell origin including undifferentiated gastric carcinoma are eligible.Xx_NEWLINE_xXHistologically confirmed, localized adenocarcinoma of the prostateXx_NEWLINE_xXThe patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the pancreas that has been documented to be resectable by standardized radiographic criteria by a pancreatic surgeonXx_NEWLINE_xXPrior therapy for pancreatic adenocarcinomaXx_NEWLINE_xXHistologically confirmed cancer (one of the following):\r\n* Metastatic pancreatic adenocarcinomaXx_NEWLINE_xXHistologically and/or cytologically confirmed and radiographically evaluable refractory metastatic colorectal adenocarcinoma for which regorafenib would be considered a therapeutic optionXx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant)Xx_NEWLINE_xXBiopsy confirmed adenocarcinoma of the prostate, performed up to 6 months prior to scheduled treatment.Xx_NEWLINE_xXPatients must have histologically documented advanced or metastatic adenocarcinoma of the colon or rectumXx_NEWLINE_xXEvidence or history of metastatic adenocarcinoma of the prostateXx_NEWLINE_xXHave a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostateXx_NEWLINE_xXFemales 18 years old and greater with histologically or cytologically confirmed diagnosis of advanced or metastatic adenocarcinoma of the breast.Xx_NEWLINE_xXGastric, Esophageal, and G-E Junction AdenocarcinomaXx_NEWLINE_xXHistological diagnosis of adenocarcinoma of the pancreasXx_NEWLINE_xXPatients must have histopathological confirmation of pancreatic adenocarcinoma prior to entering this studyXx_NEWLINE_xXHistologically or cytologically confirmed locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with acinar cell carcinoma may also be included.Xx_NEWLINE_xXPresence of islet-cell or pancreatic neuroendocrine tumor or mixed adenocarcinoma-neuroendocrine carcinomaXx_NEWLINE_xXHistologically or cytologically confirmed metastatic solid tumor, including but not limited to pancreatic adenocarcinoma, breast cancer, melanoma, renal cell carcinoma (RCC), colorectal adenocarcinoma, non-small cell lung cancer, and others approved by the principal investigatorXx_NEWLINE_xXHistological documentation of primary adenocarcinoma of the pancreasXx_NEWLINE_xXPatients with any type of recurrent pancreatic adenocarcinomaXx_NEWLINE_xXHas histopathologically confirmed gastric or GEJ adenocarcinoma with documented disease progression after 1-2 prior lines of systemic therapyXx_NEWLINE_xXHistologically or cytologically confirmed pancreatic adenocarcinomaXx_NEWLINE_xXHistologically-proven advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJXx_NEWLINE_xXHistologically confirmed pancreatic adenocarcinomaXx_NEWLINE_xXPatients with the following histologic epithelial cell types are eligible: High grade serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified (N.O.S.).Xx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinomaXx_NEWLINE_xXMale aged 18 or older with metastatic adenocarcinoma of the prostateXx_NEWLINE_xXHistologically documented adenocarcinoma or squamous cell carcinoma of the cervical esophagus, thoracic esophagus, or gastroesophageal junctionXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation, or signet cell or small cell features;Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic pancreatic adenocarcinoma (or any mixed pathology if adenocarcinoma is predominant)Xx_NEWLINE_xXHistologically- or cytologically-confirmed diagnosis of gastric or gastroesophageal junction adenocarcinomaXx_NEWLINE_xXHistological or cytological documentation of adenocarcinoma of the colon or rectumXx_NEWLINE_xXHistologically or cytologically confirmed advanced pancreatic ductal adenocarcinoma that is unresectable or metastaticXx_NEWLINE_xXPatients must have documented histological or cytological evidence of adenocarcinoma of the prostate.Xx_NEWLINE_xXHistologically or cytologically proven metastatic or inoperable pancreatic adenocarcinomaXx_NEWLINE_xXPatients must have histologically or cytologically confirmed carcinoma of the pancreas; most cases will be adenocarcinoma; cases with “undifferentiated” or “poorly differentiated” carcinoma will also be eligibleXx_NEWLINE_xXHistologically or cytologically confirmed non-resectable pancreatic adenocarcinoma with or without metastasesXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma; patients without histologically confirmed adenocarcinoma may be eligible if both the treating physician and the study principal investigator (PI) agree that the patient’s history is unambiguously indicative of advanced adenocarcinomaXx_NEWLINE_xXPathologically confirmed adenocarcinoma of the lung.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate without histological variants (including overt neuroendocrine differentiation, small cell neuroendocrine carcinoma features, sarcomatoid features, pure ductal adenocarcinoma, squamous or transitional cell carcinoma)Xx_NEWLINE_xXAdenocarcinoma of the prostateXx_NEWLINE_xXHave histologically- or cytologically-proven adenocarcinoma of the pancreas; patients with mixed histology will be excludedXx_NEWLINE_xXPathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed esophagogastric adenocarcinomaXx_NEWLINE_xXThe patient has pathologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically documented adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients with the following histologic cell types are eligible: \r\n* High grade serous adenocarcinoma\r\n* Endometrioid adenocarcinoma \r\n* Undifferentiated carcinoma\r\n* Clear cell adenocarcinoma \r\n* Mixed epithelial adenocarcinoma \r\n* Adenocarcinoma not otherwise specified (N.O.S.) \r\n* CarcinosarcomaXx_NEWLINE_xXNon-small cell lung adenocarcinomaXx_NEWLINE_xXHistological or cytological documentation of adenocarcinoma of the colon or rectum;Xx_NEWLINE_xXCytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junctionXx_NEWLINE_xXHistologically confirmed papillary serous adenocarcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPreviously untreated, apparently resectable, adenocarcinoma of the pancreas at registrationXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of the prostate without > 50% neuroendocrine differentiation or small cell histologyXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXCOHORT A: The subject must have histologically confirmed adenocarcinoma of the prostate with tissue confirmation at selected study siteXx_NEWLINE_xXHave pathologically confirmed colon or rectal adenocarcinomaXx_NEWLINE_xXNon-squamous histology including lymphoma, neuroendocrine carcinoma, adenocarcinoma, or other histologyXx_NEWLINE_xXSubject has histologically confirmed metastatic adenocarcinoma of the prostate.Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPatients must have histologically confirmed adenocarcinoma of the prostate glandXx_NEWLINE_xXGrade 3 adenocarcinomaXx_NEWLINE_xXHistologically or cytopathologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXDiagnosis of histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum.Xx_NEWLINE_xXProgressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time (PSADT) less than or equal to (<=) 10 months. PSADT is calculated using at least 3 prostate-specific antigen (PSA) values obtained during continuous ADT (androgen deprivation therapy)Xx_NEWLINE_xXParticipants must have histologically or cytologically confirmed adenocarcinoma of the prostate without >= 50% neuroendocrine differentiation or small cell histologyXx_NEWLINE_xXHistologically confirmed diagnosis of adenocarcinoma of the prostate; histologic variants of prostate cancer, including neuroendocrine features and small cell carcinoma of the prostate are excludedXx_NEWLINE_xXPART A: Known EGFR mutation and/or ALK rearrangement in NSCLC with adenocarcinoma histologyXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXEligibility for the expansion cohort: histologically or cytologically confirmed metastatic or unresectable pancreatic adenocarcinoma for which curative treatment does not existXx_NEWLINE_xXParticipants must have adenocarcinoma of the prostate that is metastatic or unresectable and for which standard curative options do not existXx_NEWLINE_xXSubjects must have a cytological or histological confirmed diagnosis of adenocarcinoma of the lung.Xx_NEWLINE_xXNon metastatic pancreatic ductal adenocarcinomaXx_NEWLINE_xXA histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.Xx_NEWLINE_xXHistologically and cytologically confirmed metastatic pancreatic adenocarcinomaXx_NEWLINE_xXAdenocarcinoma histology (including poorly differentiated non-small cell lung cancer [NSCLC], favor adenocarcinoma) of any variant, including adenosquamous histologyXx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXHistologically documented diagnosis of adenocarcinoma of the prostate (PCa) with no histologic variantsXx_NEWLINE_xXHistologically confirmed metastatic adenocarcinoma of the stomach or GEJXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate)Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate at either MSKCC or at the participating siteXx_NEWLINE_xXHistologic or cytologic diagnosis of adenocarcinoma of the pancreas.Xx_NEWLINE_xXHistologically or cytologically confirmed locally advanced or metastatic pancreatic adenocarcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, cholangiocarcinoma, gall bladder adenocarcinoma, ampullary carcinoma, adenocarcinoma of unclear primary (with a gastrointestinal primary suspected), or other primary gastrointestinal malignancy for which the treating physician feels that mFOLFIRINOX is a reasonable therapeutic optionXx_NEWLINE_xXHistologic proof of prostate adenocarcinomaXx_NEWLINE_xXCytologic or histologic proof of adenocarcinoma of the pancreas is required prior to treatment; patients with Islet cell tumors are not eligibleXx_NEWLINE_xXPatient must have a history of prostatectomy (Open Radical or Robotic Assisted) with histopathologic documentation of adenocarcinoma of the prostateXx_NEWLINE_xXThe patient has histologically or cytologically confirmed pancreatic adenocarcinoma.Xx_NEWLINE_xXHistologic diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXPatients with a histologic diagnosis of adenocarcinoma of the upper gastrointestinal tract and hepatobiliary system, including patients with any of the following diagnoses and settings who are candidates to receive radiation with concurrent continuous infusion 5-FU or oral capecitabine chemotherapy:\r\n * Pancreatic adenocarcinoma (unresected or adjuvant)\r\n * Duodenal adenocarcinoma (unresected or adjuvant)\r\n * Extra-hepatic cholangiocarcinoma (unresected or adjuvant)\r\n * Gastric adenocarcinoma (unresected or adjuvant)\r\n * Gastroesophageal junction adenocarcinoma (adjuvant)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed adenocarcinoma of the pancreas; patients who have not undergone biopsy but have highly suspected adenocarcinoma of the pancreas with borderline resectable features on imaging study may also be eligible for study and undergo the pretreatment biopsy as per protocol; the biopsy must confirm adenocarcinoma of the pancreas to continue on study; biopsy is required within 14 days of starting therapyXx_NEWLINE_xXHistological or cytological proof of colorectal or pancreatic adenocarcinomaXx_NEWLINE_xXPatients with a histologic diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXI 01. Histologically- or cytologically-confirmed prostate adenocarcinoma.Xx_NEWLINE_xXHistological or cytological documentation of adenocarcinoma of the colon or rectumXx_NEWLINE_xXHistological or cytological diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXPatients must have histologically confirmed adenocarcinoma of the small bowel or ampulla of Vater that is either unresectable or metastaticXx_NEWLINE_xXHistory of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed by the enrolling institutionXx_NEWLINE_xXSubjects must have recurrent or persistent endometrial carcinoma (including: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, dedifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified [N.O.S.], mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma) or endometrial carcinosarcoma; histologic documentation of diagnosis of carcinoma is required; microsatellite instability (MSI)-high patients will be identified based on immunohistochemistry or MSI testing of archival tumor specimens by department of pathology or via known mutations found in mismatch repair genes via the Integrated Mutation Profiling of Actionable Cancer Targets (IMPACT) assay through Memorial Sloan Kettering Cancer Center (MSKCC) Institutional Review Board (IRB)# 12-245Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate with metastatic disease.Xx_NEWLINE_xXPatient must have pathologically or cytologically Memorial Sloan-Kettering Cancer Center (MSKCC) confirmed esophageal, gastric or gastroesophageal junction (GEJ) adenocarcinoma by the enrolling institutionXx_NEWLINE_xXHistologically confirmed primary (non-recurrent) adenocarcinoma (AC) or squamous cell carcinoma of the esophagus or AC of the gastroesophageal (GE) junctionXx_NEWLINE_xXThe histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma. Patients with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, Endometrioid adenocarcinoma, Mucinous adenocarcinoma, Undifferentiated carcinoma, Clear cell adenocarcinoma, Mixed epithelial carcinoma, Transitional cell, Malignant Brenner's Tumor, Adenocarcinoma N.O.S. Patients may have co-existing fallopian tube carcinoma in-situ so long as the primary origin of invasive tumor is ovarian, peritoneal or fallopian tube.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma; GEJ adenocarcinoma may be classified according to Siewert’s classification type I, II, or IIIXx_NEWLINE_xXHistologically or cytologically proven diagnosis of metastatic ductal adenocarcinoma of the pancreas.Xx_NEWLINE_xXSubject has histologically confirmed locally advanced, metastatic or unresectable Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with mixed histology are eligible if adenocarcinoma is the predominant histology.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate.Xx_NEWLINE_xXAdenocarcinoma of the ProstateXx_NEWLINE_xXHistologically proven pancreatic adenocarcinoma with radiographically measurable OR evaluable metastatic diseaseXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the pancreas.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of an advanced nonhematological malignancy (Part A) or advanced pancreatic adenocarcinoma (Part B) that is not surgically resectableXx_NEWLINE_xXPatients with verrucous or adenocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (Siewert type II, III)Xx_NEWLINE_xXThe presence of metastatic pancreatic adenocarcinoma plus 1 of the following:Xx_NEWLINE_xXHistological diagnosis of pancreatic adenocarcinoma confirmed pathologically, ORXx_NEWLINE_xXPathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas originXx_NEWLINE_xXDiagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma (eg, lymphoma, sarcoma), adenocarcinoma originating from the biliary tree or cystadenocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without signet ring cell features.Xx_NEWLINE_xXA histological diagnosis of adenocarcinoma of the pancreas confirmed by pathology.Xx_NEWLINE_xXPatients must have histologically confirmed gastric, gastro-esophageal junction or distal esophageal adenocarcinoma (predominant histology) that is recurrent, metastatic or unresectableXx_NEWLINE_xXSubjects must have histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the intrathoracic esophagus, gastrointestinal junction or stomachXx_NEWLINE_xXHistologically confirmed primary invasive adenocarcinoma of the breastXx_NEWLINE_xXHistologically confirmed metastatic or advanced inoperable adenocarcinoma of the pancreas with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.Xx_NEWLINE_xXHistologically confirmed metastatic or advanced inoperable adenocarcinoma of the stomach or gastroesophageal junction with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.Xx_NEWLINE_xXHistologically proven adenocarcinoma of the prostate with evidence for skeletal metastases on bone scan and/or CT scan.Xx_NEWLINE_xXHistologic variants other than adenocarcinoma in the primary tumorXx_NEWLINE_xXHistologically or cytologically confirmed HER2-negative adenocarcinoma of the breastXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the colon or rectum that is metastatic.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the pancreas.Xx_NEWLINE_xXPresence of metastatic pancreatic adenocarcinoma plus 1 of the following:Xx_NEWLINE_xXHistological diagnosis of pancreatic adenocarcinoma confirmed pathologically, ORXx_NEWLINE_xXPathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreas origin in conjunction with either:Xx_NEWLINE_xXA history of resected pancreatic adenocarcinomaXx_NEWLINE_xXDiagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non-adenocarcinoma, adenocarcinoma originating from the biliary tree or cystadenocarcinomaXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHave a history of a primary adenocarcinoma of the colon and / or rectumXx_NEWLINE_xXPrior to randomization, have histological confirmation that CRC lesions were adenocarcinoma (subtypes of adenocarcinoma, e.g. mucinous adenocarcinoma are allowed). Subjects with CRC lesions of other histological types, including mixed type with predominant adenocarcinoma, will not be eligible to be randomized to study treatment.Xx_NEWLINE_xXPatients with unknown status of EGFR mutation (only for patients with adenocarcinoma histology)Xx_NEWLINE_xXPatient has histologically or cytologically confirmed localized adenocarcinoma of the pancreas including tumors in the pancreatic head, uncinate process, neck, body and tail that are potentially resectable by pancreatico-duodenectomy (Kausch-Whipple procedure); patients with islet cell or other neuroendocrine neoplasms are excludedXx_NEWLINE_xXThe subject has a proven histologic diagnosis of prostate adenocarcinoma, but may have undergone prior surgery and/or radiationXx_NEWLINE_xXPatient has histologically or cytologically confirmed borderline resectable adenocarcinoma of the pancreas; patients with islet cell or other neuroendocrine neoplasms are excludedXx_NEWLINE_xXConfirmed pancreatic ductal adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction with metastatic disease documented to involve at least liver or lung or bothXx_NEWLINE_xXLUNG ADENOCARCINOMA COHORT (COHORT 3 ONLY): Subjects must have histologically confirmed advanced (stage IIIB/IV) lung adenocarcinoma; the diagnosis will be confirmed by the Laboratory of Pathology/CCR/NCIXx_NEWLINE_xXPatients with the following histologies of endometrial cancer are not eligible for enrollment: papillary serous adenocarcinoma, clear cell carcinoma, adenosquamous carcinoma, mucinous adenocarcinoma, carcinosarcoma, sarcomaXx_NEWLINE_xXHistologically or cytopathologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of inoperable colorectal adenocarcinoma, pancreatic, hepatocellular, cholangiocarcinoma, small bowel, gastric or esophageal adenocarcinoma that carries an activated ALK or ROS1 pathwayXx_NEWLINE_xXPatients must have recurrent or persistent endometrial carcinoma; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, transitional cell carcinoma, and carcinosarcomaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate.Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma consistent clinically with androgen independent prostate cancerXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXPart B1: Gastric or Gastroesophageal Junction (GEJ) adenocarcinomaXx_NEWLINE_xXAdenocarcinoma of the breast.Xx_NEWLINE_xXSubjects must have histologically confirmed local adenocarcinoma of the prostate and have elected to proceed with radical prostatectomy as the primary curative therapyXx_NEWLINE_xXHistologically documented Stage IV ductal adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically documented Stage IV ductal adenocarcinoma of the pancreasXx_NEWLINE_xXPatients must have a histologically confirmed, unresectable pancreatic adenocarcinomaXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the breastXx_NEWLINE_xXHistologically or cytologically proven pancreatic carcinoma or adenocarcinoma; histologies other than carcinoma/adenocarcinoma will not be eligibleXx_NEWLINE_xXHistologic proof of adenocarcinoma of the prostate with clinical evidence of metastatic disease to the boneXx_NEWLINE_xXDocumented histologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXLung adenocarcinoma histology confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXPathologically confirmed: Non-small cell lung cancer (NSCLC, adenocarcinoma or squamous-cell carcinoma), Breast Cancer (HER2 positive or triple negative), Pancreatic Cancer (adenocarcinoma)Xx_NEWLINE_xXDiagnosis of histologically or cytologically confirmed prostate adenocarcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectumXx_NEWLINE_xXNon- metastasis, unresectable, adenocarcinoma pancreatic cancer patientsXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the pancreas; if the patient has mixed tumor with predominant adenocarcinoma pathology, they can be enrolledXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed colorectal adenocarcinomaXx_NEWLINE_xXHistologically-documented prostatic adenocarcinoma in >= 2 coresXx_NEWLINE_xXHave histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required, mixed histology is not allowed; subjects must have metastatic diseaseXx_NEWLINE_xXSubjects with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma N.O.S.Xx_NEWLINE_xXFor paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic diseaseXx_NEWLINE_xXHistologically or cytologically confirmed solid tumor (Part 1) or pancreatic adenocarcinoma (Part 2)Xx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the prostateXx_NEWLINE_xXHistologic diagnosis of prostate adenocarcinoma plus > 50% immunohistochemical staining for neuroendocrine markers (chromogranin, synaptophysin or neuron specific enolase)Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the breast.Xx_NEWLINE_xXHistologic confirmation of adenocarcinoma of the prostateXx_NEWLINE_xXSubject must have histologically or cytologically confirmed gastric, or gastroesophageal adenocarcinoma, or distal esophageal adenocarcinoma.Xx_NEWLINE_xXSubject must have unresectable or metastatic gastroesophageal adenocarcinoma.Xx_NEWLINE_xXSubject with previously untreated unresectable or metastatic gastroesophageal adenocarcinoma.Xx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXPatient must have histologically or cytologically confirmed colorectal adenocarcinoma or small bowel adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell featuresXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of prostate adenocarcinoma, surgically castrated or continuous medical castration (for >=8 weeks prior to Screening)Xx_NEWLINE_xXPatients with the following histologic cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specifiedXx_NEWLINE_xXHistologically-confirmed metastatic adenocarcinoma of the breast (confirmation will be done at Memorial Sloan Kettering Cancer Center [MSKCC])Xx_NEWLINE_xXHistory of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease; confirmation of diagnosis must be performed at Memorial Sloan Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate;Xx_NEWLINE_xXHistologically proven adenocarcinoma of the prostateXx_NEWLINE_xXPatients must have a cytological or histological diagnosis of adenocarcinoma arising in the pancreas; adenosquamous cancers will be acceptableXx_NEWLINE_xXHave histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required. (Subjects with mixed histology will be included if the predominant component is adenocarcinoma. Subjects must have metastatic disease.)Xx_NEWLINE_xXAdenocarcinoma of the prostateXx_NEWLINE_xXPart F - Histologically- or cytologically-confirmed gastric carcinoma, including gastric adenocarcinoma or gastroesophageal junction (GEJ) adenocarcinoma (participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the GEJ). Participants must be ramucirumab naïve. Participants must be, in the opinion of the investigator, an appropriate candidate for experimental therapy. human epidermal growth factor receptor 2 (HER2)/neu status should be documented, if known.Xx_NEWLINE_xXHistologic documentation of adenocarcinoma of the prostateXx_NEWLINE_xXThe participant has histologically or cytologically confirmed, nonsquamous (adenocarcinoma/large cell or other) NSCLC.Xx_NEWLINE_xXResectable pancreatic adenocarcinomaXx_NEWLINE_xXPathologic diagnosis of pancreatic adenocarcinomaXx_NEWLINE_xXConfirmed metastatic adenocarcinoma of the prostate that is unresponsive or refractory to hormonal therapyXx_NEWLINE_xXHistologically documented recurrent/metastatic adenocarcinoma of the breast with a recurrence on the chest wall (or its overlying skin):Xx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate;Xx_NEWLINE_xXHistologically confirmed unilateral primary invasive adenocarcinoma of the breastXx_NEWLINE_xXHave a histologically or cytologically-confirmed diagnosis of adenocarcinoma of the GEJ or stomachXx_NEWLINE_xXPhase Ib: Histologically or cytologically confirmed adenocarcinoma of the pancreas, colon or rectum which disease is advanced (defined as not surgically curable) or metastatic in whom combination treatment using fluorouracil, oxaliplatin and irinotecan is a rational optionXx_NEWLINE_xXPhase II: Patients with histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma that have not received systemic chemotherapy for advanced or metastatic disease; the definitive diagnosis of metastatic pancreatic adenocarcinoma will be made by integrating the histopathological data within the context of the clinical and radiographic dataXx_NEWLINE_xXHistologically or cytologically confirmed unresectable or metastatic esophagogastric adenocarcinomaXx_NEWLINE_xXThe study population will consist of patients who have undergone primary therapy (prostatectomy or primary radiation) for biopsy-proven adenocarcinoma of the prostate and now have biochemical-only recurrenceXx_NEWLINE_xXPatients must have estrogen and/or progesterone receptor positive histologically confirmed stage I-III adenocarcinoma of the breastXx_NEWLINE_xXHistological or cytological proof of prostate adenocarcinomaXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the prostate; if pathology is unavailable, the principal investigator (PI) may also make a determination of prostate cancer based on unequivocal clinic dataXx_NEWLINE_xXHistologically-confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate without histological variants comprising > 50% of the sample as determined by academic center central review (including neuroendocrine differentiation, small cell, sarcomatoid, ductal adenocarcinoma, squamous or transitional cell carcinoma)Xx_NEWLINE_xXEligible patients must have been diagnosed with colon or rectal adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate, clinically localized, low or low-intermediate risk disease (T1C/T2a, Gleason =< 7 [3+4], prostate-specific antigen [PSA] < 20)Xx_NEWLINE_xXHave histologically confirmed adenocarcinoma of the pancreas (including adenocarcinoma subtypes such as signet ring carcinoma, adenosquamous carcinoma, undifferentiated/poorly differentiated carcinoma, and mucinous carcinoma)Xx_NEWLINE_xXHistologically-documented localized (stage < T3) prostate adenocarcinomaXx_NEWLINE_xXNON-RANDOMIZED OBSERVATIONAL COMPONENT ELIGIBILITY:\r\nHistologically-documented localized (stage < T3) prostate adenocarcinomaXx_NEWLINE_xXPatients with the following histologic epithelial cell types are eligible:\r\n* Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not otherwise specified (N.O.S.) \r\n* However, the histologic features of the tumor must be compatible with a primary Müllerian epithelial adenocarcinoma; if doubt exists, it is recommended that the investigator should have the slides reviewed by an independent pathologist prior to entry \r\n* Patients may have co-existing endometrial cancer so long as the primary origin of invasive tumor is  ovarian or peritoneal for clarification of synchronous primary endometrial cancerXx_NEWLINE_xXPancreatic adenocarcinoma, biopsy-proven or suspectedXx_NEWLINE_xXHistologic confirmation of adenocarcinoma of the prostateXx_NEWLINE_xXHistologically confirmed resectable or borderline resectable pancreatic adenocarcinoma; pathology report formXx_NEWLINE_xXHistologically or cytologically confirmed metastatic adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the pancreas that has not been previously treated in the metastatic settingXx_NEWLINE_xXCarry a diagnosis of metastatic colon, rectum, or small bowel adenocarcinomaXx_NEWLINE_xXHistological or cytologically confirmed prostate adenocarcinomaXx_NEWLINE_xXPersonal history of pancreatic adenocarcinomaXx_NEWLINE_xXPrevious partial or complete resection of the pancreas for adenocarcinomaXx_NEWLINE_xXPatients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner’s tumor or adenocarcinoma not otherwise specified (N.O.S.); however, the histologic features of the tumor must be compatible with a primary Mullerian epithelial adenocarcinomaXx_NEWLINE_xXHistory of pancreatic adenocarcinoma (at any time)Xx_NEWLINE_xXPancreaticoduodenectomy for an indication that is not pancreatic ductal adenocarcinoma (PDAC)Xx_NEWLINE_xXCytologically or histologically confirmed of primary colon or rectal adenocarcinoma with resectable cancer, who have not received any treatments for cancerXx_NEWLINE_xXPatient had a prostate biopsy performed by Dr. Mark with the Artemis device and has adenocarcinoma of the prostateXx_NEWLINE_xXPatients with evidence of concurrent adenocarcinoma-in-situXx_NEWLINE_xXThe subject has a diagnosis of adenocarcinoma of the prostateXx_NEWLINE_xXEsophageal adenocarcinomaXx_NEWLINE_xXMale subjects 40-70 years of age diagnosed with adenocarcinoma of the prostate;Xx_NEWLINE_xXHistologically confirmed adenocarcinoma of the pancreasXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate.Xx_NEWLINE_xXHistologically-confirmed (confirmation done at Memorial Sloan-Kettering Cancer Center [MSKCC]) metastatic adenocarcinoma of the breastXx_NEWLINE_xXCOHORT I: Biopsy proven adenocarcinoma of the prostateXx_NEWLINE_xXAdenocarcinoma of the prostate, post radical-prostatectomyXx_NEWLINE_xXConfirmed diagnosis of adenocarcinoma lung cancer OR,Xx_NEWLINE_xXHistopathological proven prostate adenocarcinomaXx_NEWLINE_xXPathologically proven prostate adenocarcinomaXx_NEWLINE_xXBiopsy-proven prostate adenocarcinomaXx_NEWLINE_xXClinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinomaXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXHistopathologically proven prostate adenocarcinomaXx_NEWLINE_xXPatients should not have any type of curative or palliative therapy for pancreatic adenocarcinoma before enrolling in the studyXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXHistologically confirmed diagnosis of adenocarcinoma of the prostate; small cell or neuroendocrine tumors of the prostate are also permittedXx_NEWLINE_xXHistopathological proven prostate adenocarcinomaXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXBiopsy proven adenocarcinoma of the prostateXx_NEWLINE_xXBiopsy confirmed adenocarcinoma of the prostate within 18 months prior to enrollmentXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate; patients with small cell, neuroendocrine, and transitional cell carcinomas are not eligibleXx_NEWLINE_xXMales with known (biopsy?confirmed) primary adenocarcinoma of the prostate undergoing active surveillance scheduled for prostate biopsy (population group B)Xx_NEWLINE_xXHistologically confirmed diagnosis of colorectal adenocarcinomaXx_NEWLINE_xXHistologically confirmed primary adenocarcinoma of the prostateXx_NEWLINE_xXBiopsy proven prostate adenocarcinomaXx_NEWLINE_xXHistologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histologyXx_NEWLINE_xXHistory of adenocarcinoma of the prostate treated with radical prostatectomyXx_NEWLINE_xXPatient must have a histologic diagnosis of gastric or gastroesophageal junction adenocarcinomaXx_NEWLINE_xXClinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinomaXx_NEWLINE_xXPresence of suspicious lesion of the pancreas consistent with pancreatic adenocarcinoma; cytological confirmation is not requiredXx_NEWLINE_xXPrior resection for pancreatic adenocarcinomaXx_NEWLINE_xXHistopathological proven prostate adenocarcinomaXx_NEWLINE_xXDiagnosis of adenocarcinoma of the prostate, confirmed by transrectal ultrasound (TRUS) biopsyXx_NEWLINE_xXHistology other than adenocarcinomaXx_NEWLINE_xXHas histologically or cytologically documented adenocarcinoma NSCLCXx_NEWLINE_xXDiagnosis of prostate adenocarcinoma by transrectal ultrasound (TRUS)-guided biopsy between 28 to 90 days prior to enrollmentXx_NEWLINE_xXProstate adenocarcinoma diagnosed by biopsy within 12 months prior to study registrationXx_NEWLINE_xXA diagnosis of prostate adenocarcinoma on more than one set of prostate biopsies, on separate calendar datesXx_NEWLINE_xXA diagnosis of histopathologically confirmed rectal adenocarcinomaXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostateXx_NEWLINE_xXHistory of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).Xx_NEWLINE_xXSubject must be expected to undergo a clinically indicated surgical resection of histologically confirmed or suspected pancreatic ductal adenocarcinomaXx_NEWLINE_xXPatients with histology other than adenocarcinoma, e.g., neuroendocrine cancer or acinar cancers, are ineligible*Xx_NEWLINE_xXHistologically-confirmed diagnosis of pancreatic adenocarcinoma, mesothelioma,\r\nmesothelin-positive ovarian cancer, or NSCLC; a new biopsy is not required; the diagnostic biopsy sample will be sufficient; IHC confirmation of mesothelin positivity is not necessary for pancreatic adenocarcinoma and mesothelioma; mesothelin expression in ovarian cancer and NSCLC will be tested by IHC, and any degree of positivity (1+, 2+, or 3+) will be acceptedXx_NEWLINE_xXAny non-adenocarcinoma histologic componentXx_NEWLINE_xXCancer Registry cases for diseases other than colon or rectal adenocarcinoma and non-small cell lung cancer (squamous or adenocarcinoma histology)Xx_NEWLINE_xXPatients must have histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease.Xx_NEWLINE_xXBiliary tract adenocarcinoma.Xx_NEWLINE_xXHistologically or cytologically confirmed pancreatic ductal adenocarcinomaXx_NEWLINE_xXadenocarcinoma of the colon or rectumXx_NEWLINE_xXHistologically confirmed adenocarcinoma of the prostate gland by needle core samples with assigned Gleason scoreXx_NEWLINE_xX